Moreover, while the outcome of DS incidence did not change when assessing those with a low or moderate risk of bias, we expect that clinical trial reports are subject to misclassification bias, rooted in the lack of universally applied diagnostic criteria for DS and the unspecific nature of its symptoms, particularly for the non-M3 AML patients treated with IDH-inhibitors [7,104]. Here, IDH2 is linked to acute myeloid leukemia.